VIDEO: Diversity in clinical trials for psoriasis emphasized at AAD 2023

In this Healio exclusive video, Laura Korb Ferris, MD, discusses the importance of assessing racial and ethnic diversity in phase 3 clinical trials of risankizumab for the treatment of plaque psoriasis.

Results of the research by Andrew F. Alexis, MD, MPH, and colleagues, which were presented at the American Academy of Dermatology Annual Meeting, demonstrated that the efficacy of risankizumab was similar among races — including white, Asian, Black or African American and “other races” — and ethnicities, which included those who were Hispanic or Latino and those who were not.

Researchers found that when evaluating efficacy of risankizumab, there was not a significant difference when looking specifically at static Physician Global Assessment (sPGA) 0/1. More specifically, in the results comparing patients identifying as Hispanic or Latino vs. not identifying as these ethnicities, there was no significant difference between PASI 90, PASI 100 or sPGA 0/1.

“It’s important to make sure that the drugs that we’re using are equally safe and effective in all populations of our patients,” Ferris, professor of dermatology at the University of Pittsburgh Clinical and Translational Science Institute, said. “We also see really consistent results in terms of impact on quality of life. ... We can see that it was consistent across patients by race and ethnicity.”

Reference:

• Alexis A, et al. Short-term efficacy and racial and ethnic diversity in risankizumab phase 3 clinical trials for treatment of moderate to severe plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.